The FINANCIAL — Bayer HealthCare and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on November 22 announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related ...

Current treatments sometimes fail to help people with "wet" age-related macular degeneration -- and researchers now think they know why. Photo by Adobe Stock/HealthDay News Current treatments ...

New treatments for macular degeneration may help preserve your eyesight for longer, without the need for frequent injections. Some of these treatments include retinal gene therapy and the "port" ...

Concerns arise as Medisep 2 excludes essential eye treatment for age-related macular degeneration, risking vision for Kerala’s pensioners.

A Massachusetts General Hospital (MGH) investigator has found that increased expression of the angiogenic factor VEGF-A promotes three common aging-related eye conditions - both versions of ...

The MarketWatch News Department was not involved in the creation of this content. Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class ...

Aflibercept is a soluble decoy fusion protein that binds all isoforms of vascular endothelial growth factor (VEGF) with a greater binding affinity than ranibizumab. Intravitreal aflibercept is US Food ...

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...

People with a condition called wet age-related macular degeneration (AMD) often receive eye injections. These eye injections can help to improve vision and also stop the damage that causes vision to ...

Current treatments sometimes fail to help people with "wet" age-related macular degeneration-- and researchers now think they know why. Wet AMD is caused by an overgrowth of blood vessels in the ...